Cell Analysis Systems win Queen’s Award for Enterprise

Sphere Fluidics has been presented with a Queen’s Award for Enterprise for its single cell analysis systems which are underpinned by its patented picodroplet technology. These systems provide rapid screening and characterisation of cells to advance research and accelerate biopharmaceutical discovery and development. The Company, which was spun out from the University of Cambridge in 2010 and employs 31 people, developed the multi-award winning, Cyto-Mine® System, which integrates isolation, selective screening, sorting and imaging into a single automated platform.

Dr. Frank F. Craig, CEO, Sphere Fluidics, said: “We are immensely proud to have our pioneering approach to single cell analysis recognised with a Queen’s Award for Enterprise. This is a testament to the hard work and expertise of our dedicated team who have a deep understanding of the challenges faced by researchers in drug discovery, therapeutics and diagnostics.

"Sphere Fluidics’ technology is specifically designed to increase the chances of finding that rare molecule or cell that could lead to a life-changing medicine. Our systems help make the development of new biopharmaceuticals faster and more cost-effective, improve monoclonal antibody screening, cell line development, and overall efficiency to help accelerate research into new therapeutic modalities. Our technology is highly innovative and is covered by 148 international patents and 18 trademarks.”